- Report
- October 2025
- 477 Pages
Global
From €5192EUR$5,850USD£4,510GBP
- Report
- September 2025
- 149 Pages
Global
From €2661EUR$2,999USD£2,312GBP
- Report
- June 2025
- 400 Pages
Global
From €4392EUR$4,949USD£3,816GBP
- Report
- October 2025
- 195 Pages
Global
From €3146EUR$3,545USD£2,733GBP
€3496EUR$3,939USD£3,037GBP
- Report
- August 2025
- 182 Pages
Global
From €3146EUR$3,545USD£2,733GBP
€3496EUR$3,939USD£3,037GBP
- Report
- September 2025
- 250 Pages
Global
From €3985EUR$4,490USD£3,462GBP
- Report
- September 2025
- 250 Pages
Global
From €3985EUR$4,490USD£3,462GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1331EUR$1,500USD£1,156GBP
- Report
- January 2025
- 182 Pages
Global
From €3993EUR$4,500USD£3,469GBP
- Report
- June 2025
- 400 Pages
Global
From €4392EUR$4,949USD£3,816GBP
- Report
- April 2023
- 96 Pages
Global
From €3500EUR$4,225USD£3,147GBP
- Report
- October 2025
- 50 Pages
Global
From €2352EUR$2,650USD£2,043GBP
- Report
- March 2025
- 109 Pages
China
From €1597EUR$1,800USD£1,388GBP
- Report
- March 2025
- 215 Pages
China
From €3550EUR$4,000USD£3,084GBP

Telmisartan is a drug used to treat high blood pressure and reduce the risk of cardiovascular disease. It belongs to a class of drugs known as angiotensin receptor blockers (ARBs). Telmisartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow, leading to an increase in blood pressure. It also helps to reduce the risk of stroke, heart attack, and other cardiovascular events. Telmisartan is usually taken once a day, with or without food. It is available in tablet form and is usually taken with other medications to treat high blood pressure.
Telmisartan is a widely used drug in the cardiovascular market. It is used to treat hypertension, reduce the risk of stroke and heart attack, and improve overall cardiovascular health. It is also used to reduce the risk of developing type 2 diabetes.
Companies in the Telmisartan market include Pfizer, Novartis, Merck, Sanofi, and AstraZeneca. Show Less Read more